GoAI
Get started
Owlet, Inc. logo

Owlet, Inc.

OWLT

NYSEHealthcareMedical - Devices

Open in GoAI

Previous close

$5.20

−$0.38 · -6.81%

Aug 21, 4:00 PM ET

Pre-market

$5.30

+$0.10 · +1.92%

Aug 24, 4:37 AM ET

OWLT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

71

Undervalued

Momentum

38

Weakening

Sentiment

52

Mixed

Risk resilience

24

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Owlet, Inc. is a U.S.-based company that provides a digital platform specifically designed to support parents. Its primary objective is to equip families with immediate, valuable data and insights concerning their children. The company's product portfolio includes the Smart Sock, an advanced infant monitor that meticulously tracks a baby's oxygen saturation levels, heart rate, and sleep patterns. Another offering is the Dream Sock, a mobile application developed to help children achieve improved sleep quality. The Cam provides live video streaming functionality, allowing parents to both see and hear their baby remotely. Additionally, Owlet offers the Dream Lab, an interactive online platform that assists families in establishing healthy sleep routines. Furthermore, they market the Dream Duo, a complete system for infant sleep monitoring, which comprises a wearable sock sensor, high-definition video capabilities, and a digital sleep coaching service. Owlet, Inc. was founded in 2012 and is headquartered in Lehi, Utah.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Kurt Workman
Listed since
Nov 5, 2020
Employees
111

Market position

Day range

Current $5.20

52-week range

Current $5.20

Open
$5.525
Previous close
$5.58
Volume
252.98K
1.21× average
Average volume
208.8K
Average daily volume
Market cap
94.09M USD
Beta
1.91
Market reference 1
50-day average
$5.5144
-5.70% below average
200-day average
$8.4705
-38.61% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
279.58M USD
P/E (TTM)
-12.09×
P/B (TTM)
3.81×
P/S (TTM)
0.82×
EV / EBITDA
-7.84×
Earnings yield
-13.14%
Free cash flow yield
-3.66%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
54.72%
Operating margin
-6.45%
Net margin
-7.83%
Return on equity
-112.08%
Return on assets
-46.35%
Return on invested capital
-15.90%

Financial health

Debt / equity
0.09×
Current ratio
1.85×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends68%-1%-70%-140%Gross margin, FY2021: 46.23%Gross margin, FY2022: 33.69%Gross margin, FY2023: 41.82%Gross margin, FY2024: 50.36%Gross margin, FY2025: 50.64%Operating margin, FY2021: -73.56%Operating margin, FY2022: -122.28%Operating margin, FY2023: -53.01%Operating margin, FY2024: -25.90%Operating margin, FY2025: -7.81%Net margin, FY2021: -94.54%Net margin, FY2022: -114.64%Net margin, FY2023: -60.92%Net margin, FY2024: -16.06%Net margin, FY2025: -37.54%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 46.23%. Gross margin FY2022 33.69%. Gross margin FY2023 41.82%. Gross margin FY2024 50.36%. Gross margin FY2025 50.64%. Operating margin FY2021 -73.56%. Operating margin FY2022 -122.28%. Operating margin FY2023 -53.01%. Operating margin FY2024 -25.90%. Operating margin FY2025 -7.81%. Net margin FY2021 -94.54%. Net margin FY2022 -114.64%. Net margin FY2023 -60.92%. Net margin FY2024 -16.06%. Net margin FY2025 -37.54%.

Income trends

Revenue

105.71M USD+35.43%

Operating income

−8.26M USD+59.14%

Net income

−39.68M USD-216.51%
Income trends across reported periods124.74M USD48.61M USD−27.52M USD−103.65M USDRevenue, FY2021: 75.84M USDRevenue, FY2022: 69.2M USDRevenue, FY2023: 54.01M USDRevenue, FY2024: 78.06M USDRevenue, FY2025: 105.71M USDOperating income, FY2021: −55.79M USDOperating income, FY2022: −84.62M USDOperating income, FY2023: −28.63M USDOperating income, FY2024: −20.22M USDOperating income, FY2025: −8.26M USDNet income, FY2021: −71.7M USDNet income, FY2022: −79.34M USDNet income, FY2023: −32.9M USDNet income, FY2024: −12.54M USDNet income, FY2025: −39.68M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 75.84M USD. Revenue FY2022 69.2M USD. Revenue FY2023 54.01M USD. Revenue FY2024 78.06M USD. Revenue FY2025 105.71M USD. Operating income FY2021 −55.79M USD. Operating income FY2022 −84.62M USD. Operating income FY2023 −28.63M USD. Operating income FY2024 −20.22M USD. Operating income FY2025 −8.26M USD. Net income FY2021 −71.7M USD. Net income FY2022 −79.34M USD. Net income FY2023 −32.9M USD. Net income FY2024 −12.54M USD. Net income FY2025 −39.68M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue105.71M USD78.06M USD54.01M USD69.2M USD75.84M USD
Cost of goods sold52.18M USD38.75M USD31.42M USD45.89M USD40.78M USD
Gross profit53.53M USD39.31M USD22.59M USD23.31M USD35.06M USD
Research and development14.08M USD9.8M USD10.35M USD27.9M USD21.43M USD
Selling, general, and administrative47.72M USD49.73M USD40.87M USD80.04M USD69.42M USD
Operating expenses61.79M USD59.53M USD51.22M USD107.93M USD90.85M USD
Interest expense3.42M USD1.63M USD3.19M USD1.1M USD27.83M USD
Depreciation and amortization590K USD1.38M USD2.21M USD2.67M USD1.13M USD
Operating income−8.26M USD−20.22M USD−28.63M USD−84.62M USD−55.79M USD
Net income−39.68M USD−12.54M USD−32.9M USD−79.34M USD−71.7M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+0.89%
11 comparable reports
Latest EPS result
-0.05
Estimate -0.09 · Beat by 44.44%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.07-0.14-0.34-0.55Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual -0.07, estimate -0.51, surprise +86.27%, Beat. Q2 2025, reported May 8, 2025: actual -0.07, estimate -0.27, surprise +74.07%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.05, estimate -0.21, surprise +76.19%, Beat. Q4 2025, reported Nov 13, 2025: actual 0.03, estimate -0.23, surprise +113.04%, Beat. Q1 2026, reported Mar 5, 2026: actual -0.39, estimate -0.13, surprise -200.00%, Miss. Q2 2026, reported May 7, 2026: actual -0.09, estimate -0.18, surprise +50.00%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.05, estimate -0.09, surprise +44.44%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.043, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates35.29M28.58M21.88M15.18MQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 4, 2025: actual 20.5M USD, estimate 16.56M USD, surprise +23.77%, Beat. Q2 2025, reported May 8, 2025: actual 21.1M USD, estimate 22.15M USD, surprise -4.73%, Miss. Q3 2025, reported Aug 7, 2025: actual 26.1M USD, estimate 22.17M USD, surprise +17.75%, Beat. Q4 2025, reported Nov 13, 2025: actual 31.99M USD, estimate 26.01M USD, surprise +23.00%, Beat. Q1 2026, reported Mar 5, 2026: actual 26.6M USD, estimate 26.01M USD, surprise +2.28%, Beat. Q2 2026, reported May 7, 2026: actual 22.5M USD, estimate 20.84M USD, surprise +7.96%, Beat. Q3 2026, reported Aug 11, 2026: actual 33.9M USD, estimate 31.71M USD, surprise +6.91%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 30.56M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$108

1976.92% upside
Past 12 months12-month forecast

Price history unavailable

High $196Average $108Low $20.00

OWLT peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding OWLT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
2.67M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.36M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
315.98K
Weight
0.02%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Global X - Internet of Things ETF logoGlobal X - Internet of Things ETFSNSR
Market value
226.35K
Weight
0.11%
AUM
207.79M USD
Expense ratio
0.68%
Price / 1D
$47.2542+0.48%
Harbor Active Small Cap Growth ETF (SGRW) logoHarbor Active Small Cap Growth ETF (SGRW)SGRW
Market value
129.07K
Weight
0.44%
AUM
29.8M USD
Expense ratio
0.80%
Price / 1D
$26.4831+1.31%
Dimensional - US Small Cap ETF logoDimensional - US Small Cap ETFDFAS
Market value
126.36K
Weight
0.00%
AUM
15.92B USD
Expense ratio
0.26%
Price / 1D
$83.02+0.73%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
62.61K
Weight
0.00%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%
Dimensional - US Core Equity 1 ETF logoDimensional - US Core Equity 1 ETFDCOR
Market value
15K
Weight
0.00%
AUM
3.51B USD
Expense ratio
0.14%
Price / 1D
$84.54+0.42%

Continue in GoAI

Research OWLT

research.disclaimer